Clinical study of Jieyuguben recipe to reduce recurrent attacks of combined allergic rhinitis and asthma syndrome(CARAS)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073471

Enrollment

Unknown

Registered

2023-07-12

Start date

2023-07-12

Completion date

Unknown

Last updated

2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CARAS

Interventions

experimental group:JieYuGuBen Recipe

control group:Montelukast sodium tablets

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with chronic persistence (mild and moderate persistence) of allergic rhinitis-asthma syndrome (CARAS); (2) Those who are identified by traditional Chinese medicine as wind and phlegm obstruction, lung and spleen deficiency; (3) No contact with allergens 1 week before enrollment, no acute exacerbations were found after medical history collection and physical examination; (4) 18 years old= age = 75 years old; (5) Voluntarily receive treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Authors with acute asthma attacks within 1 week before enrollment; (2) Pregnant or lactating women, women who are preparing for pregnancy in the past 3 months, or men who are preparing for childbirth; (3) history of chronic alcohol or substance abuse or any factors affecting adherence; (4) Patients with severe heart, cerebrovascular, respiratory, liver, kidney, hematopoietic system, peptic ulcer and other primary diseases; (5) Abnormal liver and kidney function: liver (ALT or AST) exceeds the upper limit of normal value by more than 1 times or renal function (BUN or Cr) is abnormal; (6) Psychopaths, those who do not cooperate with the test; (7) Those who are allergic to the drug used to relieve depression or montelukast sodium; (8) Those who have participated in other clinical trials within 1 month; (9) Other circumstances that the investigator considers unsuitable for inclusion.

Design outcomes

Primary

Measure	Time frame
CARAS control grade;ACT score;Allergic rhinitis symptom control score;	—

Secondary

Measure	Time frame
Quantitative scoring of TCM syndrome;Asthma Quality of Life Scale;Pulmonary function test;FeNO test;Eosinophils in blood ;IgE;CRP;IL-4;IFN-?;	—

Countries

China

Contacts

Public ContactHe Yi

Xiyuan Hospital of China Academy of Chinese Medical Sciences

clampharry@sohu.com+86 10 6283 5377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026